Abstract:Woo Kyung Chung, 1 Inseung Jeon, 1 In-Jin Jang, 1 Seung-Yong Seong, 2 Seon Ae Han, 3 Kyung-Sang Yu 1 1 Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea; 2 Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea; 3 Shaperon Inc, Seoul, Republic of Korea Correspondence: Kyung-Sang Yu, Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea, Tel +82 2 3668 7833, Fax +82 2 742 9252, Email Background: HY209 is a synthesized sodium taurodeoxycholate (TDCA) that is expected to serve as a novel treatment for sepsis by inhibiting the inflammasomal activation that suppresses the production of pro-inflammatory cytokines. This study aimed to assess the safety, tolerability and pharmacokinetics (PKs) of HY209 after intravenous administration in healthy subjects. Methods: A dose-block randomized, double-blind, placebo-controlled, single ascending dose study was conducted. Eight subjects in each dose group were randomized to receive an intravenous administration of HY209 (0.1, 0.2, 0.4, 0.8 and 1.6 mg/kg) or a placebo at a 3:1 ratio. Safety and tolerability variables including adverse events (AEs) and vital signs were monitored. For the PK analysis, serial blood samples were collected for 72 hours at baseline and up to 24 hours post-dose. A power model was used to evaluate the dose-proportionality of HY209. Given that TDCA is an endogenous compound, time-matched baseline differences in plasma concentrations were analyzed. Results: A total of 39 subjects completed the study. All AEs were mild, and no serious AEs were observed. There was no significant correlation between the frequency of AEs and the administered dose. A circadian pattern was observed in the plasma TDCA concentration at baseline. After infusion, the plasma TDCA was rapidly eliminated; the plasma TDCA concentration at one hour after the end of infusion showed no significant differences from the baseline. The baseline-adjusted maximum plasma concentration of TDCA demonstrated dose-proportionality in a HY209 range of 0.1– 1.6 mg/kg. Conclusion: A single intravenous administration of HY209 was well tolerated and its systemic exposure showed dose-proportionality in a dose range between 0.1 and 1.6 mg/kg. Keywords: phase I clinical trial, pharmacokinetics, sepsis, bild acid Sepsis refers to a state of life-threatening organ dysfunction due to a dysregulated host response to infection. 1 It is one of the leading causes of sudden death in critically ill patients, usually in an intensive care unit (ICU). 2 Estimated sepsis cases in the world number approximately 50 million, and more than 10 million deaths are estimated to be related to sepsis. 3 Sepsis can cause fever, mental fog, temporary hypotension, decreased urine amounts and unexplained thrombocytopenia. 4 Previous studies have estimated that a range of sepsis mortality of about 10–20%, and even up to 50%, with a possible increase to as high as 90% with the onset of shock. 5 Guidelines published by Surviving Sepsis Campaign (SSC) recommend the systematic management of infections and hemodynamic instability with ventilation and other measures. 6 Therefore, antimicrobial therapy, infection source control, fluid therapy and vasoactive medication strategies are conventional treatments for sepsis control. 6,7 Balancing of the immune system is also highlighted during the treatment of sepsis. 8,9 In the early phase of sepsis, a hyper-inflammatory state is triggered by infection, which can then cause many of the symptoms mentioned above. However, in the later phase, immunosuppression may be caused by poor nutrient intake and secondary infections. 8,9 Given this phase transformation, many clinical trials focusing on immunosuppressant-only treatments have presented disappointing results. 10 Currently, the more precise use of immunotherapy and finding a balance between immunosuppressant use and immunostimulatory therapy are emphasized during sepsis treatments. Bile acids are amphipathic molecules synthesized from cholesterol. 11 Biosynthesis of bile acids occurs in the liver, and the products are classified as the primary bile acids (cholic acid (CA), chenodeoxycholic acid (CDCA)). 12 Gut microbiota in the intestine transforms the primary bile acids into the secondary bile acids (deoxycholic acid (DCA), lithocholic acid (LCA)) and tertiary bile acids (ursodeoxycholic acid (UDC -Abstract Truncated-

First-in-Human Safety, Tolerability, and Pharmacokinetics of Single-Dose Kukoamine B Mesylate in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase I Study

Safety, tolerability, pharmacokinetics, and efficacy of kukoamine B in patients with sepsis: A randomized phase IIa trial

A Multicenter, Randomized,double-Blinded and Placebo-Controlled Study of Acute Brain Infarction Treated by Humanurinary Kallidinogenase

A First-in-human Safety, Tolerability and Pharmacokinetics study of Benapenem in Healthy Chinese Volunteers.

Thymosin Alpha(1)- and Ulinastatin-Based Immunomodulatory Strategy for Sepsis Arising from Intra-Abdominal Infection Due to Carbapenem-Resistant Bacteria

Safety, Tolerability, and Pharmacokinetics of JX11502MA in Chinese Healthy Subjects: a First-in-human, Randomized, Double-Blind, Placebo-Controlled Study Following Single-Dose Administration.

Safety, Tolerability and Pharmacokinetics of Intravenous Sodium Taurodeoxycholate, HY209, a GPCR19 Agonist Inhibiting Inflammasomal Activation

Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

Safety and efficacy of human umbilical cord mesenchymal stem cells for the treatment of sepsis induced by pneumonia: study protocol for a single-centre, randomised single-blind parallel group trial

Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study

A randomized phase I study of the safety and pharmacokinetics of BI 1291583 in healthy Japanese male subjects

First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor

A dose‐adjusted, open‐label, pilot study of the safety, tolerability, and pharmacokinetics of STC3141 in critically ill patients with sepsis

A First-in-human Study of Brozopentyl Sodium, Following Single and Multiple Ascending Intravenous Infusion in Chinese Healthy Volunteers.

Therapeutic effects and mechanisms of Modified Ma-Xing-Shi-Gan Decoction on Klebsiella pneumoniae-induced pneumonia in mice assessed by Multi-omics

Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial

A Randomised, Double-Blind, Placebo-Controlled, First-in-human Phase I Study to Characterise the Safety, Pharmacokinetics and Immunogenicity of 9MW1411 in Healthy Chinese Subjects.

High-dose vitamin C on sepsis: Protocol of a prospective, multi-centered, double-blinded, randomized, and placebo-controlled superiority study

Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study

Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR-1707 in healthy adult subjects: two randomized, double-blind, single-ascending-dose, phase 1 studies

Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin‐A receptor antagonist